| 1 | 9975052 | Projectile and target autoionization electron emission in 700-eV Ne+-Na/M (M=Cr, Cu, Mo, and Pt) collisions. | Phys Rev B Condens Matter | 1994 Oct 1 |
2 |
| 2 | 12270053 | Differential sensitivity of sodium channels from the central and peripheral nervous system to the scorpion toxins Lqh-2 and Lqh-3. | Eur J Neurosci | 2002 Aug |
1 |
| 3 | 15385606 | Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. | J Neurosci | 2004 Sep 22 |
1 |
| 4 | 15955112 | SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. | J Invest Dermatol | 2005 Jun |
2 |
| 5 | 15958509 | Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. | Brain | 2005 Aug |
1 |
| 6 | 16301337 | Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. | Mol Pharmacol | 2006 Mar |
1 |
| 7 | 16702558 | A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. | Proc Natl Acad Sci U S A | 2006 May 23 |
1 |
| 8 | 16895935 | Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. | J Antimicrob Chemother | 2006 Oct |
4 |
| 9 | 17294067 | Characterization of a familial case with primary erythromelalgia from Taiwan. | J Neurol | 2007 Feb |
1 |
| 10 | 17430993 | A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. | J Physiol | 2007 Jun 15 |
12 |
| 11 | 17470132 | Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. | Clin Genet | 2007 Apr |
4 |
| 12 | 18027973 | Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. | Biochemistry | 2007 Dec 18 |
4 |
| 13 | 18079277 | State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. | Mol Pharmacol | 2008 Mar |
4 |
| 14 | 18249135 | Identification and characterization of the promoter region of the Nav1.7 voltage-gated sodium channel gene (SCN9A). | Mol Cell Neurosci | 2008 Mar |
2 |
| 15 | 18426592 | Nav1.7 expression is increased in painful human dental pulp. | Mol Pain | 2008 Apr 21 |
1 |
| 16 | 18485418 | Effect of dexamethasone on voltage-gated Na+ channel in cultured human bronchial smooth muscle cells. | Life Sci | 2008 Jun 6 |
6 |
| 17 | 18728100 | ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. | Mol Pharmacol | 2008 Nov |
1 |
| 18 | 18806059 | Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat. | Anesth Analg | 2008 Oct |
1 |
| 19 | 18978189 | Function and role of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle cells. | Am J Physiol Heart Circ Physiol | 2009 Jan |
2 |
| 20 | 19217209 | Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. | Pain | 2009 Apr |
2 |
| 21 | 19304393 | Two novel SCN9A mutations causing insensitivity to pain. | Pain | 2009 May |
2 |
| 22 | 19549232 | Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. | Clin Exp Dermatol | 2009 Dec |
4 |
| 23 | 19557861 | A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. | Ann Neurol | 2009 Jun |
1 |
| 24 | 19773645 | Ranolazine attenuates behavioral signs of neuropathic pain. | Behav Pharmacol | 2009 Dec |
1 |
| 25 | 19835862 | Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer. | Eur J Pharmacol | 2009 Dec 25 |
1 |
| 26 | 20038812 | Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. | J Clin Invest | 2010 Jan |
4 |
| 27 | 20529343 | Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. | Mol Pain | 2010 Jun 8 |
6 |
| 28 | 20580661 | Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models. | Neuroscience | 2010 Aug 25 |
1 |
| 29 | 20693878 | Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. | Anesthesiology | 2010 Sep |
3 |
| 30 | 20947311 | Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells. | Int J Antimicrob Agents | 2010 Dec |
1 |
| 31 | 20959280 | Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy. | Eur J Dermatol | 2010 Nov-Dec |
2 |
| 32 | 21115638 | Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents. | J Physiol | 2011 Feb 1 |
2 |
| 33 | 21570288 | Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain. | Bioorg Med Chem Lett | 2011 Jun 15 |
2 |
| 34 | 21634377 | Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. | J Med Chem | 2011 Jul 14 |
5 |
| 35 | 21715690 | Voltage-gated sodium channel Nav1.7 maintains the membrane potential and regulates the activation and chemokine-induced migration of a monocyte-derived dendritic cell subset. | J Immunol | 2011 Aug 1 |
2 |
| 36 | 21788423 | Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide. | Mol Pharmacol | 2011 Oct |
4 |
| 37 | 21882461 | Molecular Strategies for Therapeutic Targeting of Primary Sensory Neurons in Chronic Pain Syndromes | | 2010 |
2 |
| 38 | 21939494 | Two novel SCN9A gene heterozygous mutations may cause partial deletion of pain perception. | Pain Med | 2011 Oct |
1 |
| 39 | 22098589 | Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. | J Med Chem | 2012 Jan 12 |
1 |
| 40 | 22473870 | Contribution of genetic variants to pain susceptibility in Parkinson disease. | Eur J Pain | 2012 Oct |
1 |
| 41 | 22522923 | Sensitivity of cloned muscle, heart and neuronal voltage-gated sodium channels to block by polyamines: a possible basis for modulation of excitability in vivo. | Channels (Austin) | 2012 Jan-Feb |
2 |
| 42 | 22605564 | Cysteine racemization during the Fmoc solid phase peptide synthesis of the Nav1.7-selective peptide--protoxin II. | J Pept Sci | 2012 Jul |
1 |
| 43 | 23077250 | Marked difference in saxitoxin and tetrodotoxin affinity for the human nociceptive voltage-gated sodium channel (Nav1.7) [corrected]. | Proc Natl Acad Sci U S A | 2012 Oct 30 |
2 |
| 44 | 23376079 | A new Nav1.7 mutation in an erythromelalgia patient. | Biochem Biophys Res Commun | 2013 Mar 1 |
2 |
| 45 | 23382806 | Varicella-zoster viruses associated with post-herpetic neuralgia induce sodium current density increases in the ND7-23 Nav-1.8 neuroblastoma cell line. | PLoS One | 2013 |
5 |
| 46 | 23434582 | Endothelin-1-induced down-regulation of NaV1.7 expression in adrenal chromaffin cells: attenuation of catecholamine secretion and tau dephosphorylation. | FEBS Lett | 2013 Apr 2 |
6 |
| 47 | 23450472 | [Association between mutations of SCN9A gene and pain related to Parkinsonism]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2013 Feb |
1 |
| 48 | 23523779 | Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena. | Peptides | 2013 Jun |
9 |
| 49 | 23527544 | Chemical engineering and structural and pharmacological characterization of the α-scorpion toxin OD1. | ACS Chem Biol | 2013 |
4 |
| 50 | 23531742 | Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes. | Channels (Austin) | 2013 May-Jun |
1 |